PFE
Pfizer’s oncology side quest keeps paying off
Pfizer dropped detailed results from Cohort 3 of its Phase 3 BREAKWATER trial, and the headline is the kind drugmakers love to plaster on a slide deck: BRAFTOVI (encorafenib) plus cetuximab and FOLFIRI appears to nearly double progression-free survival in BRAF V600E metastatic colorectal cancer.
That matters because in cancer land, PFS is basically the “how long can the drug keep the monster from coming back?” metric. If the data hold up, this combo could become a much stronger contender in a nasty, hard-to-treat cancer setting — and that gives Pfizer another shot at turning its oncology portfolio into something more than a glittering promise.
Why investors should care
This isn’t just science-fair bragging rights. Better survival data can translate into:
- stronger physician adoption if regulators and payers buy the story
- more confidence in Pfizer’s cancer pipeline after all the patent-expiration drama elsewhere in the business
- a bigger commercial runway for a drug combo competing in a very serious market
The bigger picture
Pfizer has been on a blitz to remind Wall Street it’s still got growth engines outside of its old COVID cash machine. Oncology has been a major theme, and every clean readout helps the company prove it can build a durable next act.
Big picture: one trial doesn’t magically solve Pfizer’s identity crisis, but good cancer data is how you start writing the sequel.